Currently Viewing:
Newsroom
Currently Reading
Pembrolizumab Now Approved for First-Line Treatment of Lung Cancer in Europe and the US
February 01, 2017 – AJMC Staff
A Focus on Lifestyle and Appropriate Screening During National Cancer Prevention Month
February 01, 2017 – Surabhi Dangi-Garimella, PhD
Study Recommends Measures to Fill Quality Gaps in Oncology Care
January 31, 2017 – Surabhi Dangi-Garimella, PhD
Leaders of Cardiologists, Oncologists Decry Travel Ban
January 30, 2017 – Mary Caffrey
Need for Switch to Incretins in T2D an Indicator of Pancreatic Cancer
January 30, 2017 – Surabhi Dangi-Garimella, PhD
Healthy People 2020 Targets Achieved in 30 States for Colorectal Cancer, 28 for Cervical Cancer
January 29, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: January 27, 2017
January 27, 2017
NICE Endorses Funding for Ibrutinib in Patients With CLL
January 27, 2017 – AJMC Staff
First Trial With Universal CAR-T Treatment in Pediatric Leukemia Reports Success
January 26, 2017 – Surabhi Dangi-Garimella, PhD

Pembrolizumab Now Approved for First-Line Treatment of Lung Cancer in Europe and the US

AJMC Staff
Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.
Merck has announced that its programmed death-1 (PD-1) inhibitor, pembrolizumab (Keytruda), has been given the green light by the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer (NSCLC).

Patients with tumors that harbor a high expression of the programmed death ligand-1 receptor, without mutations in EGFR or ALK, will qualify to receive pembrolizumab instead of standard-of-care chemotherapy.

The approval follows a review of phase 3 data from the KEYNOTE-024 trial, which showed that 80% of patients on pembrolizumab were alive 6 months following treatment initiation, compared with 72% on chemotherapy. Patients on pembrolizumab also had a higher overall response rate and duration of response compared with chemotherapy. The median progression-free survival with the PD-1 inhibitor was 10.3, compared with 6 months for patients receiving chemotherapy.

“The approval of Keytruda as a first treatment instead of chemotherapy for patients who express high levels of PD-L1 has the potential to transform the way metastatic non-small cell lung cancer is treated,” Roy Banes, MD, senior vice president, head of clinical development, and chief medical officer, Merck Research Laboratories, said in a statement. “We are committed to ensuring that patients in Europe—who are in need of new treatment options—are able to quickly gain access to Keytruda.”

Pembrolizumab was approved in the United States for the same indication in October 2016.

Nivolumab, a PD-1 inhibitor developed by Bristol-Myers Squibb, and a major competitor for pembrolizumab, lagged behind in the NSCLC race following disappointing phase 3 results.


 

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up